Psychiatry

Paul Christo, MD, discusses opioid addiction during the pandemic, the role of the clinician, and offers a hopeful outlook for the future.

Experts expect an increase in mental health issues caused by the pandemic in the future.

Medication might be best used as a first-line option for patients with ADHD.

An expert discusses trends in pediatric mental health and receipt of treatment.

Higher levels of acetaminophen detected in meconium was linked to increased odds of developing ADHD by 6-7 years old.

There could be a lasting impact caused by some of the changes due to the pandemic.

This edition from the 10 Year Plan features perspective from leadership at APA and AADPRT, as well as survey results from psychiatrists.

These disparities were noted between age groups, sex, race/ethnicity, and urbanization level of residence.

For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.

Because ADHD presents differently in females than it does in males, the disorder has been underdiagnosed in females for several years.

Dr. Cerulli discusses some ways ADHD can manage the changes in routine during COVID-19.

Investigators did not find differences between children with ASD and children with ADHD after accounting for task behavior durations as percentages of total used task time.

Phthalates were particularly linked to negative behaviors in adolescents who developed ADHD.

Data shows certain personality traits are linked to a COPD patient's likelihood of active or sedentary behaviors.

Children of mothers with PCOS need additional psychological support and longer mental health follow-up.

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

A new model using proteomic data from individuals at age 12 could help predict psychotic experiences at age 18.

J. John Mann, MD, discusses potential next steps for further assessment of ketamine's antidepressant effects.

Tardive dyskinesia at treatment onset was the strongest predictor of schizophrenia relapse.

Telemedicine could be something that is still used, even after the COVID-19 pandemic is over.

Residential addiction treatment programs may not offer the best quality of care.

Approximately 50% of patients with a mTBI who experience fatigue or sleep-wake disturbances 2 weeks following the injury continue to have problems at the 3 month mark.

Investigators identify 7 themes and interventions from an analysis of studies relating to mental health and COVID-19.

An expert discusses ALKS 3831, a potential new treatment that demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

J. John Mann, MD, discusses findings in a new study that uncovers the mechanisms behind Ketamine's antidepressant effect.